Geoffrey Beran Rose Sells 7,732 Shares of Pulmonx (NASDAQ:LUNG) Stock

March 5, 2026 by InsiderTrades.com

Key Points

CEO sale: Pulmonx CEO Glendon French III sold 67,813 shares at an average of $1.43 for $96,972.59 on March 2, reducing his stake by 4.59%, and multiple insiders also sold that day (SEC filings).
New credit facility: The company closed an up-to-$60 million, five‑year credit facility (initial $40M draw, $20M milestone‑linked undrawn) that improves liquidity but carries a high effective cost (one‑month SOFR +7% with a 3.75% floor and 2% PIK) and included warrants, raising interest‑expense and dilution concerns.
Mixed fundamentals: Pulmonx beat Q4 estimates (EPS -$0.25 vs. -$0.39; revenue $22.6M vs. ~$21.7M) and improved margins, but issued 2026 revenue guidance of $90–$92M below consensus while the stock trades near ~$1.65 and carries a consensus analyst rating of Hold with an average price target of $6.81.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 7,732 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $11,056.76. Following the completion of the sale, the insider directly owned 365,734 shares of the company's stock, valued at $522,999.62. This represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Pulmonx Price Performance

Shares of LUNG traded up $0.17 during mid-day trading on Thursday, reaching $1.61. The stock had a trading volume of 1,528,616 shares, compared to its average volume of 392,735. The business has a fifty day moving average of $1.77 and a 200 day moving average of $1.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The firm has a market cap of $66.21 million, a price-to-earnings ratio of -1.14 and a beta of 0.07. Pulmonx Corporation has a 12 month low of $1.31 and a 12 month high of $8.12.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.14. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. The company had revenue of $22.60 million for the quarter, compared to analysts' expectations of $21.73 million. Equities analysts predict that Pulmonx Corporation will post -1.55 EPS for the current year.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

Positive Sentiment: Pulmonx closed a five‑year credit facility with Perceptive Advisors for up to $60M (initial $40M draw used to refinance existing debt and an undrawn $20M tied to revenue milestones). This extends maturities to 2031 and materially strengthens the company’s liquidity runway. Read More.
Positive Sentiment: Q4 results beat expectations: EPS -$0.25 vs. consensus -$0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year-over-year — supports operational progress and limits downside from prior weakness. Read More.
Positive Sentiment: D. Boral Capital reiterated a Buy rating with a $14 target, which can attract momentum buyers given the large upside versus current levels. Read More.
Neutral Sentiment: Margins and cost discipline improved: Q4 gross margin rose to ~78% and operating expenses decreased ~11% sequentially — constructive for path to profitability but still dependent on revenue re‑acceleration. Read More.
Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), signaling slower top-line growth and limiting near-term upside despite cost cuts. Read More.
Negative Sentiment: Significant insider selling was reported (CEO, general counsel and others sold shares on March 2). Multiple Form 4 filings increase perceived selling pressure and can weigh on sentiment. Read More. and Read More.
Negative Sentiment: The new financing carries a high effective cost (SOFR + 7.0% with a 3.75% floor and 2% PIK option) and the deal includes warrants — helpful for liquidity but increases interest burden and potential dilution if warrants are exercised. Read More.

Institutional Investors Weigh In On Pulmonx

Several institutional investors have recently made changes to their positions in LUNG. Susquehanna Portfolio Strategies LLC bought a new position in shares of Pulmonx during the fourth quarter valued at approximately $133,000. Engineers Gate Manager LP purchased a new stake in Pulmonx in the fourth quarter worth $106,000. ADAR1 Capital Management LLC lifted its position in shares of Pulmonx by 65.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company's stock worth $785,000 after purchasing an additional 140,913 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Pulmonx by 144.6% during the fourth quarter. AQR Capital Management LLC now owns 58,919 shares of the company's stock valued at $130,000 after purchasing an additional 34,828 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Pulmonx in the 4th quarter worth about $31,000. Institutional investors own 91.04% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LUNG. Weiss Ratings restated a "sell (e+)" rating on shares of Pulmonx in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Pulmonx from a "sell" rating to a "hold" rating in a report on Sunday, November 16th. Finally, D. Boral Capital restated a "buy" rating and set a $14.00 price objective on shares of Pulmonx in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $6.81.

Check Out Our Latest Analysis on LUNG

About Pulmonx

(Get Free Report)

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.